We are studying how to make medical test results easier for patients to understand. Pathology reports, which explain what doctors find in tissue samples, are often written for medical professionals and can be hard for patients to read. In this study, we are testing whether artificial intelligence (AI) can help explain these reports in plain language. Patients having a routine screening procedure will read a sample report with or without an AI-generated explanation. Then they will answer questions about how well they understood the report and how they felt about it. We want to learn if using AI helps people better understand their health information and feel more confident making decisions. This will help improve the way test results are shared in the future.

The purpose of this project is to advance understanding of the relationship of food and eating characteristics with gastrointestinal symptoms on a population level, by examining the frequency, associated factors, and quality of life and emotional effects of eating-associated gastrointestinal symptoms.

Objectives 1. Identify barriers to research engagement for patients who have undergone colectomy and pouch surgery for UC. 2. Develop and prioritize a patient-centered CER agenda to prevent and/or treat pouchitis and CLDP, unique, unfortunate, and rare diseases. 3. Identify, train, and empower a cohort of patients with or at-risk for pouchitis and CLDP to effectively partner in designing and conducting high-priority patient-centered CER.

To understand the relationship between biomarkers (found in the blood) and health outcomes among adults diagnosed with hepatocellular carcinoma who are receiving a liver transplant.

To determine the effect of dual targeted therapy with an anti-integrin (vedolizumab [VDZ]) and a Janus kinase (JAK) inhibitor (tofacitinib [TOF]) on clinical remission.

To (1) test the Rome V Diagnostic Questionnaire, a new version of a questionnaire designed to assess the presence of 25 different Disorders of Gut-Brain Interaction (DGBI), (2) estimate the population prevalence of each of these 25 disorders in the adult population of different countries, (3) evaluate which demographic and personal factors are associated with having these DGBI, and (4) assess their impact on quality of life and emotional wellbeing.

What is the real-world effectiveness of etrasimod in adult patients ages ≥18 years and <65 years with moderately to severely active UC?

• To provide investigators in the Division of Gastroenterology with the sources of clinical information for basic research and clinical studies of inflammatory bowel diseases. • To provide optimal and standardized collection of stool for such studies.

EGID Partners is an online cohort of patients with eosinophilic gastrointestinal diseases (EGIDs), like eosinophilic esophagitis (EoE), eosinophilic gastritic (EG), eosinophilic gastroenteritis (EGE), and/or eosinophilic colitis (EC). It is a way to conduct important clinical research through surveys, and by filling out the initial survey, as well as follow-up surveys every 6 months, you can help answer important questions about living with EGIDs. We are also looking for people without EGIDs to provide information as well, so we can make comparisons between those do and don't have EGIDs. Adults as well as parents/caregivers of children are eligible. Find out more at www.egidpartners.org

Demonstrate the safety and feasibility of rifaximin in the prevention of recurrent pouchitis after an initial episode of acute pouchitis.